Sugi Predict

Sugi Predict / Compounds / SCHEMBL1019112

SCHEMBL1019112

SCHEMBL1019112

CCCCc1ccc(N=C=O)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.55
▸ CYP2D6 P10635 2/20 0.55
▸ CYP2C9 P11712 2/20 0.55
▸ CYP1A2 P05177 2/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ CYP4Z1 Q86W10 1/20 0.55
▸ CYP4F11 Q9HBI6 1/20 0.55
▸ CYP4F12 Q9HCS2 1/20 0.55
▸ SKP2 Q13309 1/20 0.51
▸ TRPA1 O75762 1/20 0.41
▸ HPGD P15428 3/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CA2 P00918 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8156692 0.90 CYP3A4 (0.43) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL2221380 0.88 CYP3A4 (0.47) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL28113211 0.87 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL6896659 0.84 CYP3A4 (0.55) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL11856225 0.81 CYP3A4 (0.50) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL15357 0.81 CYP3A4 (0.48) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL29379077 0.81 CYP3A4 (0.48) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL29565064 0.81 CYP3A4 (0.48) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL27749580 0.80 SKP2 (0.41) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL10963754 0.79 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108912599-B Filter film obtained by compounding nitrile rubber and phenolic resin 长春峰泰汽车胶业有限公司 2020-12-25 — — CN claimed
CN-108912599-A The filter film that a kind of nitrile rubber and phenolic resin compound 长春峰泰汽车胶业有限公司 2018-11-30 — — CN claimed
EP-4713378-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2026-03-25 — — EP disclosed
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 — — EP disclosed
WO-2024236000-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2024-11-21 — — WO disclosed
EP-4464727-A1 ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-11-20 — — EP disclosed
US-20240343941-A1 DUAL-CURE RESIN COMPOSITION COMPRISING URETDIONE-CONTAINING COMPOUND AND ITS USE IN 3D PRINTING BASF SE (DE) 2024-10-17 — — US disclosed
EP-4380990-A1 DUAL-CURE RESIN COMPOSITION COMPRISING URETDIONE-CONTAINING COMPOUND AND ITS USE IN 3D PRINTING BASF SE (DE) 2024-06-12 — — EP disclosed
US-20240150515-A1 Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers COVESTRO DEUTSCHLAND AG (DE) 2024-05-09 — — US disclosed
CN-117836344-A Dual cure resin composition comprising uretdione containing compounds and use thereof in 3D printing 巴斯夫欧洲公司 2024-04-05 — — CN disclosed
WO-2024033289-A1 A PHOTOCURABLE OLIGOMER CONTAINING URETDIONE GROUPS, METHOD OF PREPARING THE OLIGOMER AND DUAL-CURE RESIN COMPOSITION CONTAINING THE OLIGOMER THEREOF BASF SE (DE) 2024-02-15 — — WO disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 — — EP disclosed
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors NOVARTIS AG (CH) 2007-03-15 — — US disclosed
CN-1784400-A Quinuclidine derivatives binding to muscarinic M3 receptor NOVARTIS AG (CH) 2006-06-07 — — CN disclosed
EP-1631569-A2 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS Novartis AG (CH) 2006-03-08 — — EP disclosed
US-20050239841-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 — — US disclosed
WO-2005051381-A1 Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) BIOVITRUM AB (SE) 2005-06-09 — — WO disclosed
WO-2005037839-A1 NORCANTHARIDIN DERIVATIVE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF ENTOMED (FR) 2005-04-28 — — WO disclosed
WO-2004096800-A2 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS NOVARTIS AG (CH) 2004-11-11 — — WO disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors CHRM3, CHRM2, CHRM1 CYP3A4 890/4885CYP2D6 1109/4885CYP2C9 1481/4885
US-20050239841-A1 New compounds MCHR1, NPY1R, HCRTR1 CYP3A4 1263/4885CYP2D6 838/4885CYP2C9 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.